CELESTIAL
Post Approval Registry
(Corox OTW, Endocardial, Left VEntricular STeroIdL eAd, 
BipoLar Post Approval Registry)
November 16, [ADDRESS_13957] approval registry.  Therefore, this do cument should be 
maintained in a secure location and should not be copi[INVESTIGATOR_14585] e available for 
review by [CONTACT_14591].
CELESTIAL R EGISTRY PROTOCOL
Revision: 16-NOV-2010 CONFIDENTIAL: Do Not Copy or Distribute Wi thout Sponsor Approval Page 1
Table of Contents
1. INTRODUCTION ................................................. ............................................................... ....................5
1.1 Name [CONTACT_8151].............................................. ............................................................... ................. 5
1.2 Overview and Background ..................................... ............................................................... .........5
1.2.1 Overview .................................................. ............................................................... ............ 5
1.2.2 Background ................................................ ............................................................... .......... 6
1.2.3 Prior Clinical Experience................................. ............................................................... ..... 6
[IP_ADDRESS] everesT Study Overview.................................. ............................................................... ..............6
[IP_ADDRESS] Implant Success Rate Comparison......................... ............................................................... .......7
[IP_ADDRESS] Corox BP LV Lead Measurements ........................... ............................................................... .....7
[IP_ADDRESS] Freedom from Corox BP LV Lead Related Complications..... .......................................................9
1.3 Device Descriptions......................................... ............................................................... ..............10
1.3.1 Corox BP LV Leads......................................... ............................................................... ...10
[IP_ADDRESS] Corox OTW BP............................................ ............................................................... ................10
[IP_ADDRESS] Corox OTW-S BP .......................................... ............................................................... ..............10
2. STUDY DESIGN................................................. ............................................................... ...................12
2.1 Study Endpoints ............................................. ............................................................... ...............12
2.2 Primary Endpoint 1:  Safety of Corox OTW (-S) LV Leads Pacin g – Overall Complication-Free 
Rate ........................................................... ............................................................... .........................12
2.3 Primary Endpoint 2: Safety of Corox BP LV Leads – Individual Complication Rates ..................[ADDRESS_13958] ................................. ............................................................... ............14
2.6 Registry Size ............................................... ............................................................... ..................15
2.7 Data Analysis............................................... ............................................................... .................. 16
2.7.1 Trend Analyses ............................................ ............................................................... ......17
2.7.2 Missing Data .............................................. ............................................................... ........18
2.8 Study Organization.......................................... ............................................................... ..............18
2.8.1 Electronic Data Capture (EDC)............................. ............................................................[ADDRESS_13959] Approval Registry Design............................... ............................................................... .......20
3.2.1 Procedure................................................. ............................................................... ..........20
3.2.2 Study Visits .............................................. ............................................................... ..........20
3.2.3 Screening Visit ........................................... ............................................................... ........21
3.2.4 Enrollment Visit (within 30 days of screening visit)...... .....................................................21
3.2.5 Routine and Unscheduled Follow-Ups........................ ......................................................22
4. STUDY DOCUMENTATION AND DATA COLLECTION...................... ..............................................22
4.1 Electronic Case Report Forms (eCRFs)........................ ............................................................... 22
4.2 Data Quality Control ........................................ ............................................................... ..............23
4.3 Patient Retention........................................... ............................................................... ................23
CELESTIAL R EGISTRY PROTOCOL
Revision: 16-NOV-2010 CONFIDENTIAL: Do Not Copy or Distribute Wi thout Sponsor Approval Page 2
5. PATIENT CONSENT.............................................. ............................................................... ...............24
6. CONFIDENTIALITY AND RISK ANALYSIS ............................ ...........................................................24
6.1 Patient Data Confidentiality ................................ ............................................................... ...........24
6.2 Risks and Risk Minimization................................. ............................................................... .........24
7. MONITORING ................................................... ............................................................... ....................24
7.1 Summary ..................................................... ............................................................... ..................24
7.2 Registry Monitors........................................... ............................................................... ................ 25
7.3 Monitoring.................................................. ............................................................... ....................25
7.4 Registry Completion ......................................... ............................................................... .............25
7.5 Deviation from the Investigational Plan..................... ............................................................... ....26
7.6 Adverse Events .............................................. ............................................................... ...............26
7.7 Clinical Events Committee ................................... ............................................................... .........28
7.8 Patient Death............................................... ............................................................... .................. 29
7.9 IRB Approval ................................................ ............................................................... .................29
7.10 Other Institutions and Physicians .......................... ............................................................... ........29
8. RECORDS AND REPORTS .......................................... ............................................................... .......30
8.1 Investigator Records........................................ ............................................................... ..............30
8.2 Investigator Reports ........................................ ............................................................... ..............30
8.3 Sponsor Records............................................. ............................................................... ..............31
8.4 Sponsor Reports............................................. ............................................................... ...............32
APPENDIX A: DEFINITION OF TERMS................................ ............................................................... .....33
APPENDIX B: TIMELINE ........................................... ............................................................... .................37
Table of Figures
Figure 1: Corox OTW Bipolar LV Leads........................... ............................................................... ........ 11
Table of Tables
Table 1: Implant Success Rate Comparison ....................... ............................................................... ......7
Table 2: Corox BP LV Lead: Pacing Parameters ................... ............................................................... ... 8
Table 3: Comparison of Freedom from Adverse Events in the Corox BP LV Lead to Other 
Published Study Results ........................................ ............................................................... .....9
Table 4: Adverse Event Exclusions .............................. ............................................................... ...........13
Table 5: Primary Safety Endpoints Sample Sizes ................. ............................................................... .16
CELESTIAL R EGISTRY PROTOCOL
Revision: 16-NOV-2010 CONFIDENTIAL: Do Not Copy or Distribute Wi thout Sponsor Approval Page [ADDRESS_13960]-APPROVAL REGISTRY
PROTOCOL SIGNATURE [CONTACT_14623] C ELESTIAL protocol and 
any attachments, and provides the necessary assurances that thi s registry will be 
conducted according to all stipulations of the protocol, includ ing all statements regarding 
confidentiality, and according to local legal and regulatory re quirements and applicable 
U.S. federal regulations, ICH and GCP guidelines .
PRINCIPAL INVESTIGATOR :
[INVESTIGATOR_14586]: Date:
Name (please print)
Signature [CONTACT_1782]:
CELESTIAL R EGISTRY PROTOCOL
Revision: 16-NOV-2010 CONFIDENTIAL: Do Not Copy or Distribute Wi thout Sponsor Approval Page 4
PROTOCOL SUMMARY
Title: CELESTIAL Post-Approval Registry
Design: This study is a long-term post approval registry designed to fol low at least
2500 patients implanted with BIOTRONIK’s Corox BP left ventricula r lead.
Each patient will be followed for 5 years.
Purpose: The purpose of this post-approval registry is to confirm long-t erm safety and 
successful biventricular pacing for BIOTRONIK’s Corox BP left ve ntricular (LV)
pacing leads as used in conjunction with any BIOTRONIK CRT pulse generator (CRT pacemaker (CRT-P) or CRT defibrillator (CRT-D)). The  
evaluation of safety will be based on the analysis of Corox BP L V lead related 
adverse events. The CELESTIAL post-approval registry will provide data to 
permit characterization of any LV lead failures contributing to  patients losing 
CRT. Additionally, acute and chronic LV lead parameters for paci ng thresholds 
and impedance will be evaluated.
Patient Population: Patients who require treatment for advanced heart failure throug h any CRT-P
or CRT-D. Patient must be successfully implanted with a BIOTRON IK CRT 
system, including a Corox BP LV lead, from 7-180 days prior to en rollment.
Enrollment: This post approval registry will include a minimum of [ADDRESS_13961].
Clinical Sites: Up to 100 sites in the [LOCATION_002] and internationally.
Primary Endpoints: The purpose of Primary Endpoint 1 is to evaluate the overall in cidence of 
serious adverse events related to the Corox BP LV leads. The pur pose of
Primary Endpoint 2 is to evaluate the incidence of each type of  serious 
adverse event that contributes to Primary Endpoint 1. 
Secondary Endpoint: The following secondary endpoints will also be evaluated during  the study:
1. Successful biventricular pacing in a BIOTRONIK CRT device at 
scheduled CELESTIAL registry follow-up visits through [ADDRESS_13962]-
enrollment
2. Serious adverse event rates for SAEs excluded from primary sa fety 
endpoint (listed in Table 4) through [ADDRESS_13963]-enrollment
Sponsor: BIOTRONIK, Inc.
Clinical Studies Department6024 SW Jean RoadLake Oswego, Oregon  [ZIP_CODE]
CELESTIAL R EGISTRY PROTOCOL
Revision: 16-NOV-2010 CONFIDENTIAL: Do Not Copy or Distribute Wi thout Sponsor Approval Page [ADDRESS_13964] approval registry for the BIOTRON IK’s Bipolar Over-
the-Wire (OTW) steroid-eluting left ventricular (LV) pacing lea ds: Corox OTW Bipolar 
(BP), Corox OTW-S BP, and Corox OTW-L BP, further referred to as C orox BP LV lead 
throughout this protocol. For this study, the Corox BP LV lead is  utilized in conjunction 
with any market-released BIOTRONIK Cardiac Resynchronization Ther apy (CRT)
device.
1.[ADDRESS_13965]-approval registry is to confirm long-ter m safety and reliability of
the Corox BP LV lead as used in conjunction with any BIOTRONIK C ardiac 
Resynchronization Therapy pacemaker or defibrillator (CRT-P or CRT-D). The 
CELESTIAL post-approval registry will provide data to fully char acterize LV lead 
failures, from implant through [ADDRESS_13966] approval registry.
All patients will be screened to ensure they are eligible to pa rticipate, and will sign an 
informed consent prior to enrollment into the registry. The info rmed consent is designed 
to allow the collection of all pertinent LV lead data at implan t and up to the time of 
enrollment. During this study, the CRT devices will be programmed to provide cardiac 
resynchronization therapy. Additionally, all patients will contin ue to receive conventional 
pharmacological therapy for the treatment of CHF and tachyarrhy thmias.
CELESTIAL R EGISTRY PROTOCOL
Revision: 16-NOV-2010 CONFIDENTIAL: Do Not Copy or Distribute Wi thout Sponsor Approval Page 6
1.2.2 Background
BIOTRONIK developed the Corox BP LV leads for use in biventricular  pacing systems.
These leads are polyurethane coated and designed to minimize an y system related 
restrictions regarding implantation. Corox BP LV lead can be in troduced into the
coronary venous system either by [CONTACT_14592]. Furthermo re, the guidewire can 
be introduced into the lead body from either end (distal or prox imal). Sensing and 
pacing through the lead can be programmed in various configurat ions, allowing optimal 
parameters to be programmed acco rding to each individual patien t.
Each of these leads is offered with a different type of fixation.  The Corox OTW BP has a
three dimensional pre-shaped helical tip to achieve a stable po sition in larger veins, 
while Corox OTW-S BP has a tip with a bend at the distal end fo r stable placement in 
smaller veins (‘wedge position’). Finally, the Corox OTW-L BP ha s a dual-curve shape 
that is designed to achieve a stable position in larger veins.
The CELESTIAL Post Approval Registry is designed to document the cl inical 
experience of the Corox BP LV leads in the [LOCATION_002] and inte rnationally as 
required by [CONTACT_14593] P070008, dated May 12, 2008.
1.2.3 Prior Clinical Experience
[IP_ADDRESS] everesT Study Overview
The clinical investigation everesT: “Evaluation of the new BIOT RONIK 
Resynchronization+ICD System” evaluated the safety and effectiv eness of the 
Lumax HF-T [ADDRESS_13967] iveness was based on an 
equivalence (non-inferiority) comparison between the implant su ccess rate of the Corox 
BP LV leads and rates reported in prior studies for endocardial L V leads. The evaluation 
of safety was based on analysis of the incidence of Corox BP LV lead related adverse 
events, defined as any complications or observations judged by [CONTACT_14594].
CELESTIAL R EGISTRY PROTOCOL
Revision: 16-NOV-2010 CONFIDENTIAL: Do Not Copy or Distribute Wi thout Sponsor Approval Page 7
[IP_ADDRESS] Corox OTW-L BP Pre-Market Evaluation Overview
The Corox OTW-L BP Pre-Market Evaluation (PME) was completed to assess the 
clinical performance of the Corox OTW-L BP lead. The study was p erformed by 
[CONTACT_14595], investigator asse ssment, and lead related 
observations. Lead data were collected at implant, hospi[INVESTIGATOR_14587] -discharge and 1-month 
follow-up. This pre-market evaluation was conducted as an obser vational registry 
without pre-defined endpoints or sample size calculations.
[IP_ADDRESS] Implant Success Rate Comparison
Left ventricular lead placement success rates are dependent on s everal key factors, 
including: lead design, patient coronary vein anatomy, physicia n expertise, and 
familiarity of placing LV leads.
D u r i n g  t h e  e v e r e s T  s t u d y ,  C o r o x  O T W  B P  L V  l e a d s w e r e s u c c e s s f u l l y  implanted in 
91.5% of patients (97/106), and Corox OTW-S BP LV leads were succ essfully 
implanted in 89.5% of patients (34/38). Overall, the Corox OTW BP and Corox OTW-S
BP LV leads were successfully implanted in 91.0% of patients (1 31/144). During the 
Corox OTW-L BP LV lead PME, 82.6% of patients (71/86) were succ essfully implanted 
with the lead. Table 1 compares the implant success rates of the Corox BP LV leads to 
other published study results.
Table 1: Implant Success Rate Comparison
LV Lead N
BIOTRONIK Corox OTW and Corox OTW-S BP LV leads (everesT) 131/144 (91.0%)
BIOTRONIK Corox OTW-L BP LV leads (Corox OTW-L BP PME) 71/86 (82.6%)
BIOTRONIK Corox OTW UP Steroid 121/132 (91.7%)
St. Jude Aescula 1055K (P030035) 125/146 (85.6%)
St. Jude Aescula 1055K (P030054) 155/175 (88.6%)
St. Jude QuickSite 1056K (P030035) 153/162 (94.4%)
Medtronic Attain Models: 2187, 2188, 4189 (P010031) 374/424 (88.2%)
Guidant Easytrak Models: 4510, 4511, 4512, 4513 (P010012) 448/517 (86.7%)
[IP_ADDRESS] Corox BP LV Lead Measurements
At implant and all routine follow-ups during the everesT clinica l study and the Corox 
OTW-L PME, investigators were required to use the implanted pul se generator to obtain 
ventricular lead measurements, including pacing thresholds and l ead impedance. All 
measurements were made with a pulse width of 0.5 milliseconds. I ntra-operative data 
were measured with an external pacing system analyzer or through  the pulse generator.
CELESTIAL R EGISTRY PROTOCOL
Revision: 16-NOV-2010 CONFIDENTIAL: Do Not Copy or Distribute Wi thout Sponsor Approval Page [ADDRESS_13968] data fro m the Corox OTW-L
BP LV lead PME.
Table 2: Corox BP LV Lead: Pacing Parameters
Corox BP (everesT)
Pacing Threshold 
(Volts @ 0.50 ms)Corox BP (everesT)
Lead Impedance
(Ohms)Corox OTW- LBP
Pacing Threshold
(Volts @ 0.5 ms)Coro xOTW- LBP
Lead Impedance
(Ohms)
Implant
Number of Tests 121 115 31 30
Mean ± SD 1.2 ± 0.9 839 ± 262 1.0 ± 0.7 723 ± 191
Range 0.2 - 4.5 362 -1720 0.3 - 3.6 470 - 1164
Pre-discharge 
Follow-up
Number of Tests 128 121 32 32
Mean ± SD 1.5 ± 1.3 732 ± 219 1.0 ± 0.6 681 ± 216
Range 0.3 - 7.5 305 -1748 0.3 - 2.6 316 - 1273
One-month 
Follow-up
Number of Tests 108 103 28 31
Mean ± SD 1.3 ± 1.2 806 ± 245 1.1 ± 0.7 745 ± 185
Range 0.3 - 7.5 374 -1652 0.3 - 3.2 427 - 1164
Three-month 
Follow-up
Number of Tests 99 94 N/A N/A
Mean ± SD 1.2 ± 1.1 788 ± 202 N/A N/A
Range 0.4 - 5.2 346 -1379 N/A N/A
Six-month 
Follow-ups
Number of Tests 15 15 N/A N/A
Mean ± SD 0.8 ± 0.6 886 ± 194 N/A N/A
Range 0.4 - 2.7 646 -1407 N/A N/A
All lead impedance and pacing threshold values observed in the e veresT study and the 
Corox OTW-L BP LV lead PME are clinically acceptable. Low pacing thresholds and
appropriate lead impedance values may allow the physician to pro gram lower outputs 
while maintaining an adequate safety margin, thereby [CONTACT_14596] y extending the service
life of the pulse generator.
CELESTIAL R EGISTRY PROTOCOL
Revision: 16-NOV-2010 CONFIDENTIAL: Do Not Copy or Distribute Wi thout Sponsor Approval Page 9
[IP_ADDRESS] Freedom from Corox BP L V Lead Related Complications 
During the everesT clinical study, the freedom from Corox BP LV l ead related 
complications post-implant was studied. The results were compared to  a predetermined 
performance criterion and to the results of other similar prospe ctive LV lead clinical 
trials. Patients who terminated the study before completing all follow-up procedures 
were included up to the point of their study exit. During the Co rox OTW-L BP LV lead 
PME, adverse events data were collected through at least [ADDRESS_13969], although none were reported.
Freedom from Corox BP LV lead related adverse events compares fav orably with 
results from other manufacturers. Table 3 presents freedom from Corox BP LV lead
related adverse events along with other published results.
Table 3: Comparison of Freedom from Adverse Events in the Corox B PL V  L e a d
to Other Published Study Results
Study Results
BIOTRONIK Corox OTW BP97.9% *
2 complications in 
97 pts
BIOTRONIK Corox OTW-S BP100% *
0 complications in 
34 pts
BIOTRONIK Corox OTW-L BP100% †
0 complications in 
32 pts
BIOTRONIK Corox OTW UP Steroid (helix)92.9%
[ADDRESS_13970]. Jude QuickSite 1056K LV lead (P030054)96.1% *
[ADDRESS_13971]. Jude Aescula 1055K LV lead (P030035)88.2%
25 complications in 
24 pts.
Medtronic Attain LV lead Models 4189 (P010031)85.1%
49 complications in 
44 pts.
Guidant Easytrak LV Lead Models 4510, 4511, 4512, 4513 
(P010012)87.8%
53 complications in 
517 pts.
*Freedom from LV lead related complications at 3 months
† Freedom from LV lead related complications at 1 month
CELESTIAL R EGISTRY PROTOCOL
Revision: 16-NOV-2010 CONFIDENTIAL: Do Not Copy or Distribute Wi thout Sponsor Approval Page [ADDRESS_13972] 0.014 inch  guidewire can be 
introduced from either the distal or proximal end into the lead  body. This allows 
alternate usage of a stylet or guidewire until the lead is adva nced and properly fixated in 
a coronary vein. The leads are equipped with a “true” stylet sto p near the tip, which 
allows full straightening of, and maximal load transmission to,  the distal end of the lead 
with a stylet. An integrated distal tip seal situated inside th e lead body prevents intrusion 
of fluids into the lead lumen during implantation.
The MP35N/Ag lead conductor core is insulated with silicone and externally coated with 
polyurethane up to the beginning of the helix. A steroid / silic one collar behind the tip 
electrode is designed to slowly elute 0.5 mg of dexamethasone ac etate (DXA). A
second steroid / silicone collar is located next to the ring an d slowly elutes 0.5 mg of 
dexamethasone acetate (DXA).
The leads are available in two different lengths (77 & 87 cm), which  are designated as 
Corox OTW (-S or -L) 75-BP and Corox OTW (-S or -L) 85-BP, respecti vely; dedicated 
implant tools include several ScoutPro guiding catheters and Gal eo guidewires with 
varying designs, as well as commercially available balloon cathete rs to facilitate 
coronary sinus angiography for visualization of the venous anat omy.
[IP_ADDRESS] Corox OTW BP
This LV lead model has a helical ly pre-shaped distal end design ed to provide atraumatic
fixation within a coronary vessel (Figure 1 left). The tip is ele ctrically active with an area 
of 5.0 mm2and a diameter of 5.85 F (1.95 mm). The electrically active ring  has an area 
of 8.0 mm2and a diameter of 5.85 F. The tip and ring electrodes are separa ted by 18 
mm. To improve pacing and sensing, both electrodes are fractally  coated with iridium to 
enhance charge transfer between the conductive sections of the lead and the 
electrolyte.
[IP_ADDRESS] Corox OTW-S BP
This LV lead model has a bend in the distal end enhanced with a silicone screw to 
provide atraumatic fixation within a narrow coronary vessel (Fig ure 1 right). The tip is 
electrically active with an area of 5.0 mm2and a diameter of 5.85 F (1.95 mm). The 
electrically active ring has an area of 8.0 mm2and a diameter of 5.85 F. The tip and ring 
electrodes are separated by 18 mm. To improve pacing and sensin g, both electrodes 
are fractally coated with iridium to enhance charge transfer be tween the conductive 
sections of the lead and the electrolyte.
[IP_ADDRESS] Corox OTW-L BP
The Corox OTW-L BP is a subsequent model of the currently marke ted Corox OTW BP 
and Corox OTW-S BP leads. The Corox OTW-L BP lead features desi gn elements 
inherited from the predecessor models, such as electrode shape,  size and spacing, 
CELESTIAL R EGISTRY PROTOCOL
Revision: 16-NOV-2010 CONFIDENTIAL: Do Not Copy or Distribute Wi thout Sponsor Approval Page 11
however, the Corox OTW-L BP has a new passive fixation structur e (Figure 1 bottom). 
This structure is a dual-curved pre-shape, covering approximate l y  [ADDRESS_13973] of lead, and is designed t o achieve a stable position in  larger veins.
Figure 1: Corox BP LV Leads

CELESTIAL R EGISTRY PROTOCOL
Revision: 16-NOV-2010 CONFIDENTIAL: Do Not Copy or Distribute Wi thout Sponsor Approval Page [ADDRESS_13974]-approval registry is a multi-center, prospec tive, non-randomized, 
5 year data collection registry. The registry is designed to ga ther long term safety and 
reliability data on BIOTRONIK’s Corox BP LV leads. All patients enrolled into the clinical 
study will have an implanted BIOTRONIK CRT system, including a Corox BP LV lead, 
and will be enrolled from 7-[ADDRESS_13975]-implant, and are mea nt to be seen according 
to each institution’s standard of care, but not to exceed a foll ow up time frame of (1)
every 6 months for CRT pacemakers (CRT-Ps) or (2) every 4 months for CRT 
defibrillators (CRT-Ds). At enrollment, information will be coll ected regarding patient 
medical history, demographics, and other secondary data or data of interest specifically 
pertaining to the implant and status of the LV lead. At each follo w up, a determination 
will be made whether the system is providing appropriate bivent ricular pacing.
Additionally, the electrical parameters of the left ventricular lead will be collected, and 
any LV lead related adverse event will be documented.
The primary safety endpoints are constructed to capture all LV le ad-related serious 
adverse events (SAEs) that require additional invasive interventi on to resolve. Individual 
analysis of each serious adverse event (SAE) will be conducted and reported 
throughout the study. The low probability of SAE mandates the r egistry study size of a 
minimum of 2000 patients. 
A secondary effectiveness endpoint will utilize a responder ana lysis of the 
success/failure of the CRT generator implanted with the Corox B P LV lead to deliver 
long-term biventricular pacing t hrough [ADDRESS_13976]-implant.
2.1 S TUDY ENDPOINTS
This clinical investigation includes the assessments of two prima ry safety endpoints
related to the Corox BP LV leads, and several secondary endpoints  that include an
evaluation of the long-term delivery of biventricular pacing by [CONTACT_14597].  The hypotheses associated with the primary safety end points are presented 
below.
2.2 P RIMARY ENDPOINT 1: S AFETY OF COROX BP LV L EADS PACING –
OVERALL COMPLICATION -FREE RATE
The purpose of primary endpoint [ADDRESS_13977] a LV lead failure . 
CELESTIAL R EGISTRY PROTOCOL
Revision: 16-NOV-2010 CONFIDENTIAL: Do Not Copy or Distribute Wi thout Sponsor Approval Page [ADDRESS_13978] been collected and re ported by [CONTACT_14598] (P050045, P050023, P030035, P010031, P010015, and P0100 12). While these 
SAEs will not be counted toward primary endpoint, they will be collected and analyzed 
as pre-specified secondary endpoints.  
Table 4: Adverse Event Exclusions
Adverse Event ExclusionsEstimates of rates from 
prior studies
Inability to place LV Lead 10 - 14%
Lead dislodgements up to [ADDRESS_13979] implant 
procedure1.9 - 9%
High LV pacing threshold, i ntermittent LV capture, 
no capture of LV lead3.6 - 5.6%
Diaphragmatic/pectoral stimulation 0.2 - 2.9%
Infection 1.6 - 2.3%
Atrial lead, ICD lead, or generator adverse events 
requiring additional interventions1.6 - 36.8%
Non LV lead related  hospi[INVESTIGATOR_602] 27.4 - 48.9%
Non LV lead related death 6.2 - 18.9%
Implant procedure related complications such as 
CS dissection, CS perforation, pneumothorax, 
arrhythmias, cardiac tamponade, hematoma1.5 - 13.3%
LV lead related thrombosis <0.5%
Implant damage to LV lead (e.g. accidental cut to 
lead body during pocket revision, device 
replacement, etc.)0.2 - 0.9%
Twiddler’s syndrome 0.2%
Assuming that the expected Corox BP LV lead-related serious adverse  event rate
(proportion of subjects with at least one SAE), excluding the a bove, is 7.5% or less, 
then the primary safety endpoint will be evaluated in the followi ng testable hypothesis in 
a noninferiority format.   
Ho: The serious adverse event-free rate (SAEFR) for the Corox BP L V Leads at [ADDRESS_13980]-enrollment is inferior to 92.5%
SAEFR +  92.5%
Ha: The serious adverse event-free rate (SAEFR) for the Corox BP L V Leads at [ADDRESS_13981]-enrollment is not inferior to 92.5%
SAEFR +  > 92.5%
CELESTIAL R EGISTRY PROTOCOL
Revision: 16-NOV-2010 CONFIDENTIAL: Do Not Copy or Distribute Wi thout Sponsor Approval Page 14
Where, ( ) is the clinically significant difference for establishing non i n f e r i o r i t y .   A  
rejection of the null hypothesis would indicate that the seriou s adverse event-free rate is 
not inferior to 92.5% within ( ).
2.3 P RIMARY ENDPOINT 2: S AFETY OF COROX BP LV L EADS –INDIVIDUAL 
COMPLICATION RATES
Each of the individual types of serious adverse events contribu ting to primary safety 
endpoint 1 will be evaluated separately in the following superi ority hypotheses:
Ho: The individual serious adverse event rate (SAEIndividual) for  a given type of SAE 
for the Corox BP LV Leads at [ADDRESS_13982]-enrollment is equal to  1%
SAEIndividual =  1%
Ha: The individual serious adverse event rate (SAEIndividual) for a given type of SAE 
for the Corox BP LV Leads at [ADDRESS_13983]-enrollment is not equa l to 1%
If the two-sided, 95% upper confidence bound is no more than 1%  for individual serious 
adverse events, then the null hypothesis will be rejected for th at SAE type.
2.[ADDRESS_13984]-enrollm ent
2. Serious adverse event rates for SAEs excluded from primary sa fety endpoint 
(listed in Table 4) through [ADDRESS_13985]:
1. Patient implant data (collected retrospectively from medical c hart review)
2. Demographic information3. All cause adverse events4. BIOTRONIK RA and RV/ICD lead electrical performances5. Returned product analyses
CELESTIAL R EGISTRY PROTOCOL
Revision: 16-NOV-2010 CONFIDENTIAL: Do Not Copy or Distribute Wi thout Sponsor Approval Page 15
6. Extraction experience
7. Comparison of data collected between Home Monitoring and in-o ffice device 
interrogations
2.6 R EGISTRY SIZE
The estimated sample size requirement is based on both primary safety endpoints: a
noninferiority comparison of the overall SAE free-rate to 92.5%  at 5 years, excluding 
those SAEs listed in Table 4, and a non-powered, superiority com parison for those 
individual lead-related SAE to 1% at 5 years.  The sample size fo r primary safety 
endpoint 1 was calculated based on the following assumptions:  
Assumptions for primary safety endpoint 1
Study Design:  nonrandomized registry
Type I error (alpha):  0.05 (one-sided for noninferiority)
Statistical power:  80%
Noninferiority delta:  5%
Estimated SAE-Free Rate at 5 years: 92.5% for Corox BP LV Leads
For primary safety endpoint 1, a total of 240 evaluable subjects i mplanted with Corox 
BP LV leads would be required to demonstrate the noninferiority w ithin 5% of a SAE 
free-rate of 92.5%.   Assuming a 50% loss to follow-up rate over  5 years of follow-up, a 
total of 480 (240/0.5) subjects would be required to evaluate pr imary safety endpoint 1.
Enrollment will seek to achieve 240 evaluable subjects for each  of the Corox BP LV 
leads.
Assumptions for primary safety endpoint 2
Estimated individual SAE rate at 5 years:  0.4%
Allowable two-sided, upper 95% confidence bound:  1%
For primary safety endpoint 2, a total of 1000 subjects would be  required to 
demonstrate a two-sided, upper 95% confidence bound of 1%, assu ming an expected 
individual SAE rate of 0.4% (no more than 4 patients with an SAE  out of 1000).  
Assuming a 50% loss to follow-up rate over 5 years (10% per year ), a total of 2000
(1000/0.5) enrolled patients would be required for evaluation of primary safety endpoint
2.
The required sample sizes for the two primary safety endpoints are summarized in 
Table 5.
CELESTIAL R EGISTRY PROTOCOL
Revision: 16-NOV-2010 CONFIDENTIAL: Do Not Copy or Distribute Wi thout Sponsor Approval Page 16
Table 5: Primary Safety Endpoints Sample Sizes
Primary 
Safety 
Endpoint 1:
Overall SAE 
free-ratePrimary
Safety
Endpoint 2:
Individual 
SAE rates
Sample Size of Evaluable Patients 240 1000
Total with 50% Loss to Follow-Up 
over 5 years480 2000
Due to the addition of the Corox OTW-L BP in the study, the tot al sample size was 
increased to 2500 to allow for su fficient enrollment of patient s with this lead.
Study attrition
For the sample size calculation, a maximum loss to follow-up of  10% per year (50% 
over 5 years) was assumed. The loss to follow-up rate encompass es all causes for 
subjects to be exited from the study, including subject death, device explants, patient 
directed withdrawals, physician directed withdrawals, and loss of contact [CONTACT_14599]. BIOTRONIK will make every effort to limit the loss to follow-up, for reasons 
other than subject death and device explants unrelated to devic e design or 
performance, to less than 20% of the total registry enrollment cohort.
Minimum cohort size
The pre-specified secondary analysis will be conducted as an ad  hoc analysis, meaning 
no testable hypothesis is being stated.  Therefore, the minimal  cohort size to analyze 
each lead model is based on an assumption of an equal 1/[ADDRESS_13986]. If no 
evidence is found of differences between the Corox OTW BP, Corox  OTW-S BP, and 
Corox OTW-L BP LV leads (p > 0.05), then the results will be con sidered poolable for 
purposes of testing the protocol hypotheses associated with the  two primary endpoints. 
If evidence of differences is found for a given endpoint, then t he hypotheses for that 
endpoint will additionally be tested separately for each LV lead.  
CELESTIAL R EGISTRY PROTOCOL
Revision: 16-NOV-2010 CONFIDENTIAL: Do Not Copy or Distribute Wi thout Sponsor Approval Page [ADDRESS_13987] 
comparing a binomial proportion (overall SAE free-rate at 5 years ) to 92.5%, with a 
noninferiority delta of 5%. Equivalently, the upper, one-sided 95% confidence bound for 
the absolute difference between the overall SAE free-rate and 9 2.5% must not exceed 
5%.
The evaluation of primary safety endpoint [ADDRESS_13988], two-sided 95% 
confidence interval for the observed, individual SAE rates at 5  years.  The upper bound 
of these 95% confidence intervals must be less than 1%.
The secondary endpoint of successful biventricular pacing will be summarized as a 
success rate at each of the scheduled CELESTIAL follow-up visits through [ADDRESS_13989], 95% confidence i ntervals.
The secondary endpoint of other SAEs at 5 years, which were exc luded from the 
primary safety analyses (listed in Table 5), will also be summa r i z e d  a s  S A E  r a t e s   
together with their associated ex act, 95% confidence intervals.  
The secondary endpoints of pacing threshold and impedance measu rements for the 
Corox BP LV leads will be summarized at scheduled visits where they were evaluated, 
using standard measures, including means, standard deviations, medians, minimums, 
and maximums.
The secondary endpoint for overall incidence of serious adverse  events that meet the 
primary endpoint [ADDRESS_13990] pre-
specified performance levels (92.5% for overall freedom from Co rox BP LV lead-rated 
SAEs, 1% for individual SAE rates). To monitor the ongoing inciden ce of any potential 
SAEs against the accumulating follow-up exposure post-enrollmen t, Kaplan-Meier 
actuarial survivor curves will be prepared at the reporting int ervals for these safety 
outcomes. Root causes for any failures, regardless of the incid ence rates, will be 
investigated.  
If the observed cumulative survival rates fall below the 5-year target values (92.5% of 
overall freedom from SAEs, 99% for individual SAEs) at any time  during the study, or 
are projected to fall below the target values, then BIOTRONIK wil l summarize the 
observed data and the results of its failure investigations, an d report the findings to the 
FDA at or before the next scheduled status report.  If at any ti me a single unanticipated 
serious adverse event or device failure, or combination of even ts, is believed to have 
implications regarding the safety  of current or future patients , then this will be reported 
immediately to the FDA.
CELESTIAL R EGISTRY PROTOCOL
Revision: 16-NOV-2010 CONFIDENTIAL: Do Not Copy or Distribute Wi thout Sponsor Approval Page 18
2.7.2 Missing Data
The reasons for any missing data in the study will be documente d.  The sponsor will 
examine both missing-data patterns, which describe which values  a r e  o b s e r v e d  a n d  
which are missing, and the missing-data mechanisms, which conce rn the relationship 
between missingness and the values of variables in the study da ta set [R.J.A. Little and 
D.B. Rubin, 2002, Statistical Ana lysis with Missing Data, 2nd e dition, Wiley and Sons].
For evaluation of the primary study endpoints (safety endpoints  1 and 2), only patients 
who achieve [ADDRESS_13991] (LVCF) will be used to estimate the 
values at the final 5-year follow-up evaluation.
2.8 S TUDY ORGANIZATION
2.8.1 Electronic Data Capture (EDC)
MedNet Solutions Incorporated is a privately-held company that specializes in Web-
based clinical database and data management technology. MedNet’s  responsibility is to 
partner with BIOTRONIK in the development, implementation, and on-going support of 
a system for an eClinical Solution including EDC of clinical tr ial data for the CELESTIAL
post-approval registry. MedNet will configure a web-based eClin ical system to meet the 
specific goals and needs of BIOTRONIK for the CELESTIAL registr y. MedNet will host 
the Oracle database utilized for the EDC system. This system is  21 CFR Part 11 
compliant and will be the conduit for the electronic case repor t form (eCRF) data entry, 
data validation, and access to real-time configured functions, tools, and reports for 
BIOTRONIK, specified investigational sites, and any other parti es authorized by 
[CONTACT_14600].
CELESTIAL R EGISTRY PROTOCOL
Revision: 16-NOV-2010 CONFIDENTIAL: Do Not Copy or Distribute Wi thout Sponsor Approval Page [ADDRESS_13992] ed for participation should 
be from the investigator's general patient population according  to the inclusion and 
exclusion criteria described bel ow. Patients declining participa tion will be documented 
on a screen failure log describing the primary reason.
3.1.1 Indications
Corox BP LV Lead
The Corox OTW BP, Corox OTW-S BP, and Corox OTW-L BP left ventric ular pacing 
leads are bipolar steroid-elutin g leads, intended for permanent  implantation in the left 
ventricle via the coronary veins to provide pacing and/or sensi ng when used in 
conjunction with a compatible IS-[ADDRESS_13993]-approval registry, any legally-marketed BIOTRONIK CR T device may be
used (e.g. CRT-D: Lumax HF-T and any future CRT-D; CRT-P: Strato s LV and any 
future CRT-P).
3.1.2 Contraindications
Corox BP LV Lead
The use of the Corox BP LV leads is contraindicated under the foll owing circumstances:
Coronary sinus anomalies
Tissue in the coronary sinus area that has been damaged by [CONTACT_14601] a single systemic dose of up to 1.0 mg o f dexamethasone 
acetate (DXA)
3.1.[ADDRESS_13994]-approval registry, patie nts are required to meet 
the following inclusion criteria prior to enrollment:
Successfully implanted BIOTRONIK CRT system, including a Corox BP L V lead,
from 7-180 days prior to enrollment.
Able to understand the nature of the registry and give informed  consent 
CELESTIAL R EGISTRY PROTOCOL
Revision: 16-NOV-2010 CONFIDENTIAL: Do Not Copy or Distribute Wi thout Sponsor Approval Page [ADDRESS_13995] igational site
Age greater than or equal to 18 years
3.1.4 Exclusion Criteria
To support the objectives of this registry, the exclusion crite ria at the time of patient 
enrollment include:
Enrolled in any IDE clinical study
Planned cardiac surgical procedures or interventional measures within the next [ADDRESS_13996] CRT programmed “ON”. Additionally, BIOTRONIK Home 
Monitoring should be activated in all subjects. Standard Home Mo nitoring reports will be 
available to investigators.  Home monitoring data can be utiliz ed to assist in triage and 
diagnosis of LV lead-related adverse events.
3.2.2 Study Visits
The specific visits that are part of this registry are provided  in the following bullets, and
the procedures are described in more detail in the following se ctions:
Screening Visit
Enrollment
Routine and unscheduled follow-ups through [ADDRESS_13997]-implant ( every 
subsequent follow up that is scheduled according to each instit ution’s 
standard of care)
CELESTIAL R EGISTRY PROTOCOL
Revision: 16-NOV-2010 CONFIDENTIAL: Do Not Copy or Distribute Wi thout Sponsor Approval Page 21
3.2.3 Screening Visit
Prior to enrollment, the patient’s background and history must be reviewed in order to 
ensure they are an appropriate candidate for the registry. In a ddition, all patients must 
satisfy the inclusion and exclus ion criteria prior to enrollmen t, including having an 
implanted BIOTRONIK CRT system ut ilizing a Corox BP LV lead.  Aft er the patient has 
passed this screening process, informed consent must be obtaine d from the patient 
prior to initiating any reg istry-related procedures.
The following are required at this visit:
Ensure registry candidacy by [CONTACT_14602]
3.2.4 Enrollment Visit (within 30 days of screening visit)
After Informed Consent has been obtained and the patient has be en determined to be 
eligible for the registry, data is collected in the Enrollment V isit. Typi[INVESTIGATOR_14588].
The following are required at the Enrollment Visit:
Collect retrospective implant information from medical chart rev iew
Date of implant
Implant approach/method, and venous access
Implant location of pulse generator and implanted leads
Implant procedure durations, if available
Collect patient demographics (gender, height, weight, etc.)
Medical history of patient
Bradycardia or ICD indication with Heart Failure
NYHA classification
LVEF %, if available; date and method obtained
Collect information on implanted system (pulse generator and le ads 
manufacturer/model, serial numbers, etc.)
Record electrical parameters of the implanted leads
Record any cardiac related adver se event between implant and th e 
enrollment visit
Programming parameters should be set to best suit the needs of the patient. If adequate 
system function, including effective CRT, cannot be obtained, th e patient should not be 
enrolled in this registry.
CELESTIAL R EGISTRY PROTOCOL
Revision: 16-NOV-2010 CONFIDENTIAL: Do Not Copy or Distribute Wi thout Sponsor Approval Page [ADDRESS_13998] approval registry can b e implanted with either 
a CRT Pacemaker (CRT-P) or a CRT Defibrillator (CRT-D). Follow-up  schedules for 
these devices vary by [CONTACT_14603], but typi[INVESTIGATOR_812] 3-[ADDRESS_13999] of care, but not to exceed eve ry 6 months. All scheduled 
follow up windows are ± 1 month.
Any time a patient is seen outside of a required follow-up wind o w  a c c o r d i n g  t o  e a c h  
site’s pre-determined specific follow-up scheduling practice, t hat visit is considered an 
unscheduled follow-up. Each site Principal Investigator (PI) an d Clinical Research 
Coordinator (CRC) will be trained to identify and schedule foll ow-ups to meet this 
expectation. Additionally, the EDC will provide assistance in i dentifying properly 
scheduled follow-ups according to this protocol by [CONTACT_14604] (eCRF).
The following are required at each follow-up visit:
Interrogate programmed parameters
Determine lead electrical parameters
Evaluate device diagnostics and programmed parameters to ensure  CRT is 
programmed “ON” and the device is correctly providing CRT therap y
Record % of CRT pacing
Determine if there are any cardiac-related Adverse Events. If th ere are, 
complete the Adverse Event eCRF
Complete all appropriate eCRF’s
4. STUDY DOCUMENTATION AND DATA COLLECTION
4.1 E LECTRONIC CASE REPORT FORMS (ECRF S)
Original data will be collected from each investigational site and recorded into a secure 
Electronic Data Capture (EDC) application hosted by [CONTACT_14605], Minneapolis, 
Minnesota, and audited and monitored by [CONTACT_14600]. 
Information from electronically delivered source data (e.g. pro grammers) will be 
captured and stored in a validated environment until the end of  the study.
The investigator will be required to use his/her electronic sig nature to verify the content 
of the data reported in the eCRFs.
Patient follow-up is required for all subjects enrolled in this clinical registry. The follow-
up visit date is based on the Co rox BP LV lead implant date, and a re to be used for:
CELESTIAL R EGISTRY PROTOCOL
Revision: 16-NOV-2010 CONFIDENTIAL: Do Not Copy or Distribute Wi thout Sponsor Approval Page 23
Screening Visit
Enrollment (7-180 days after Corox BP LV lead implant or lead revisio n)
Medical History and Implant (at enrollment)
Routine follow-ups (every 3-4 months for a CRT-D and every 6 mo nths for a 
CRT-P, ± 1 month)
Unscheduled cardiac related physician or hospi[INVESTIGATOR_14589] 5 Year follow-up (± 1 month)
All cause Adverse Events
Study Exit
Patient Non-Compliance
4.[ADDRESS_14000] 
inaccuracies and inconsistencies. 
4.3 P ATIENT RETENTION
Although the CELESTIAL Study sample size has been calculated wi th a 10% patient 
attrition rate per year (50% in 5 years), patient retention in a [ADDRESS_14001] t o follow-up.  The EDC 
system includes an overview of each patient’s follow-up schedul e, including the 
tolerance windows for each follow-up. The EDC system also provides  a patient follow-
up scheduling tool in the form of a Visit Scheduler Report. Thi s report allows research 
personnel to become alerted to and track all study patients tha t should be scheduled for 
upcoming follow-ups. Additionally, the EDC system will automati cally provide a bi-
weekly action item list to each site coordinator in the form of  email, which includes all 
patients that are due for scheduling.
Finally, to ensure protocol and follow-up compliance at all par ticipating investigational 
sites, BIOTRONIK monitors will conduct monitoring visits (see S ection 7). Monitoring 
visits include a review of pati ents that may be lost to follow- up.
CELESTIAL R EGISTRY PROTOCOL
Revision: 16-NOV-2010 CONFIDENTIAL: Do Not Copy or Distribute Wi thout Sponsor Approval Page 24
5. PATIENT CONSENT
Patient participation in this re gistry is voluntary. It is requ ired that all patients sign an 
IRB approved Patient Information and Consent Form (ICF) prior to p articipation in the 
registry. Patient informed consent must be obtained before enrol lment and any protocol 
related procedures. To assist with the consent process, BIOTRONI K will provide a
template patient ICF to participating sites.
The investigator is required to inform the sponsor and the revi ewing IRB within [ADDRESS_14002] (IRB) ma y review and/or copy 
the study records.
6.[ADDRESS_14003]-approval registry c onducted using legally marketed devices implanted 
according to their approved labeling. BIOTRONIK foresees no addit ional risks 
associated with this registry beyond those stated in the labeli ng for the respective pulse 
generators and leads.
7. MONITORING
7.1 S UMMARY
BIOTRONIK, Inc. is the "sponsor" of the clinical registry. A spons or is defined as an 
entity that initiates but does not conduct a post-approval regi stry. BIOTRONIK’s
responsibility as the post-appro val registry sponsor is to ensur e protocol and regulatory 
compliance through periodic monitoring of the investigation. BIO TRONIK has 
determined that this clinical investigation is not a significant risk study, as it concerns 
only legally marketed devices that are used in accordance with approved labeling. 
However, BIOTRONIK requires IRB review and a Patient Information  and Consent form 
for all after-market research.
CELESTIAL R EGISTRY PROTOCOL
Revision: 16-NOV-2010 CONFIDENTIAL: Do Not Copy or Distribute Wi thout Sponsor Approval Page 25
7.2 R EGISTRY MONITORS
Registry monitors are trained, qualified, and designated by [CONTACT_14606] a registr y at the clinical site. The ad dress for submitting clinical 
data to BIOTRONIK for this registry is:
BIOTRONIK, Inc.
Attn: CELESTIAL RegistryClinical Studies Department6024 Jean RoadLake Oswego, Oregon [ZIP_CODE]
Clinical data may also be submitted by [CONTACT_12100]: ([PHONE_238]
For technical assistance 24 ho urs a day, call: ([PHONE_239]
7.[ADDRESS_14004] the inv estigator and other site 
personnel. During periodic monitoring visits, assessment of the  study site will include 
the following:
Completion and submission of the required eCRFs and other applic able 
registry documentation
Continued acceptability of the facilities
Adherence to the clinical protocol
Adherence to the applicable FDA regulations regarding the oblig ations of the 
investigator and maintenance of records
7.[ADDRESS_14005]-approval registry site upon completi on or termination of 
the registry or of the investigator’s participation. At the sponso r’s request, an 
investigator will return any equipment and pertinent information in their possession. The 
sponsor will provide a final report to each investigational sit e as required by [CONTACT_14607]. After FDA has agreed to terminate this registry, BI OTRONIK personnel will 
conduct a registry closure visit. During this final visit, BIOTR ONIK will verify records and 
ensure that the investigator understands any applicable regulat ory requirements,
including those related to record retention. The investigator mu st retain records related 
to the registry for a period of 2  years after the investigation is completed.
CELESTIAL R EGISTRY PROTOCOL
Revision: 16-NOV-2010 CONFIDENTIAL: Do Not Copy or Distribute Wi thout Sponsor Approval Page [ADDRESS_14006]-approval r egistry.
BIOTRONIK categorizes protocol non-compliance instances as eithe r violations or
deviations. Both protocol violations and deviations will be repo rted to FDA in the form of 
progress reports as necessary.
Protocol violations are defined as instances where the protocol  requirements and/or 
r e g u l a t o r y  g u i d e l i n e s  w e r e  n o t  f o l l o w e d ,  a n d  a r e g e n e r a l l y  m o r e  serious in nature. 
Protocol violations are considered to potentially affect the sc ientific soundness of the 
study and/or the rights, safety, or welfare of subjects. Protoc ol violations include, but are 
not limited to, failure to obtain consent and patient inclusion/ exclusion violations. These 
violations will be reported to FDA in accordance with applicabl e regulatory timelines,
and the site must notify the reviewing IRB. Protocol violations  must also be reported to 
the sponsor via Case Report Forms.
Protocol deviations are deviations from the requirements of the  protocol in such a 
manner whereby [CONTACT_14608]. Protoco l deviations are less 
serious in nature and do not require IRB notification as long a s they do not effect the 
rights, safety, or welfare of the registry patient. Protocol dev iations from the post-
approval registry must be reported to the sponsor via Electronic D ata Capture.
7.6 A DVERSE EVENTS
The investigator will be required to assess the association of e ach reported adverse 
event to the implant procedure, implanted system including the generator, any lead, or 
the Corox BP LV lead. For each o f these relationships, the inve stigators will indicate 
whether the Adverse Event is not related, related, possibly rela ted, or unknown. 
All Adverse Events will be adjudicated by [CONTACT_14609] C ommittee (see Section 
7.7 Clinical Events Committee). The Clinical Events Committee ( CEC) will have the 
responsibility to adjudicate all Adverse Events into one of the  following three final 
classifications: related, not related, or unknown.
CELESTIAL R EGISTRY PROTOCOL
Revision: 16-NOV-2010 CONFIDENTIAL: Do Not Copy or Distribute Wi thout Sponsor Approval Page [ADDRESS_14007] that individual 
unknown event contribute to or be included in the evaluation of  primary safety endpoint 
1 (overall complication-free rate ). Patients with an adjudicate d relatedness SAE 
classification of unknown for a specific type of individual SAE  will not have that 
individual unknown event contribute to or be included in the ev aluation of that type of 
SAE in primary safety endpoint 2. However, for purposes of Kapla n-Meier actuarial 
analyses, described in Section [ADDRESS_14008] completed follow-up visit.
For the purposes of this registry, an adverse event is consider ed to be implant related if 
any one of the following occurred:
Coronary sinus dissection
Coronary sinus perforation
Pneumothorax
Arrhythmias
Cardiac Perforation with or without tamponade
Non-healing pocket dehiscence requiring intervention
Hematoma 
Other event requiring surgical intervention
Additionally, for purposes of this registry, an adverse event i s considered to have 
occurred at any point if both of  the following conditions are m et:
Condition One (definitions can be found in Appendix A: Definitio n of Terms)
Infection
Cardiac perforation with or without tamponade
Lead dislodgment
High pacing threshold, intermi ttent capture, no lead capture
Diaphragmatic/pectoral stimulation
Lead impedance out of range, high impedance
Lead impedance out of range, low impedance
Lead related thrombosis
Implant damage to lead (e.g. accidental cut to lead body during  pocket revision, 
device replacement, etc.)
Premature battery depletion
Suspected lead failure
Suspected generator failure
Twiddler’s Syndrome
Lead undersensing or loss of sensing
Skin erosion
CELESTIAL R EGISTRY PROTOCOL
Revision: 16-NOV-2010 CONFIDENTIAL: Do Not Copy or Distribute Wi thout Sponsor Approval Page 28
Condition Two:
Lead pacing polarity or pacing mode reprogrammed due to suspecte d lead 
failure
Lead surgically repositioned
Lead surgically explanted
Lead surgically replaced
Lead surgically abandoned
Lead abandoned and pacing disabled
Lead use continued based on medical judgment despi[INVESTIGATOR_040] a known cl inical 
performance issue
Other lead related surgery performed 
Note: If Condition One is corrected by [CONTACT_14610] (other 
than changing the polarity or pacing mode) and no other invasiv e action was taken, then 
the event will not be considered an adverse event and should no t be reported. Similarly,
programming changes in pacing polar ity/vector or pacing mode th at are not due to a 
suspected lead failure will likewise not be considered an adver se event and should not 
be reported. For example, electrical reprogramming of the pacing  polarity to eliminate 
diaphragmatic stimulation will not be considered an adverse eve nt.
The adverse events that the IRB considers reportable are depend ent on the particular 
IRB.  The protocol-defined Adverse Events not related to the Co rox BP LV lead are 
detailed in Table 4. To avoid underreporting, BIOTRONIK recomme nds that, at a 
minimum, the investigational site reports the adverse events de tailed above that occur 
during the CELESTIAL post approval  study to BIOTRONIK and their  IRB.
The investigational site should report the Adverse Event on the  Adverse Event eCRF.
Additionally, registry sites may report adverse events through M edWatch, FDA’s 
adverse event reporting tool for market-released devices. As def ined in BIOTRONIK’s 
internal procedures, these adverse events may be reported by [CONTACT_14611]’s MedWatch reports.
7.7 C LINICAL EVENTS COMMITTEE
A Clinical Events Committee (CE C) consisting of at least 3 inde pendent 
Electrophysiologists will be established to review and adjudica te all adverse events that 
occur during the study according to the protocol definitions. T he CEC will be blinded to 
the investigational site and the patient identity.  The CEC mem bers will not participate 
as investigators, in order to minimize any potential bias.
The CEC will create a study specific charter defining the adver se event adjudication 
process, specifically detailing review guidelines along with app ropriate response 
timelines.
CELESTIAL R EGISTRY PROTOCOL
Revision: 16-NOV-2010 CONFIDENTIAL: Do Not Copy or Distribute Wi thout Sponsor Approval Page 29
7.8 P ATIENT DEATH
Personnel at the investigational  site should notify BIOTRONIK as  soon as possible 
concerning any patient death during the investigation. This not ification should include a 
completed Study Exit eCRF and copy of the notification of death ( death report) sent to 
the IRB. The death report should include all of the following, if available:
date and time of death
place of death
identification of the rhythm at t he time of death, if known (in clude any 
available documentation)
immediate cause of death
any other circumstances  surrounding the death
whether the death was device related
Any implanted legally marketed devices that are explanted, incl uding the Corox BP LV 
lead should be returned to BIOTRONIK for analysis.
7.[ADDRESS_14009] (IRB) approval is required from each  site prior to participation 
in this clinical registry. Patient enrollment may not begin unt il the IRB and BIOTRONIK
have granted approval for the registry site. IRB approval is als o required throughout the 
duration of this clinical investigation. If IRB approval is wit hdrawn for a site, BIOTRONIK
must be notified within [ADDRESS_14010] igator might not be 
immediately available to provide the necessary medical care for  a patient with a registry
device (e.g. when a patient goes to the emergency room for medi cal treatment). In any 
such situations, the IRB and investigator must continue to prov ide oversight for that 
patient’s medical care and rights as a research subject. BIOTRO NIK will ensure that the 
necessary support personnel are available to any physician prov iding immediate care 
for a patient in order to answer questions about the device and provide guidance in 
collecting the necessary documentation required for the post-ap proval registry.
Documentation obtained will then be forwarded to the approved i nvestigator for review 
and signature.
CELESTIAL R EGISTRY PROTOCOL
Revision: 16-NOV-2010 CONFIDENTIAL: Do Not Copy or Distribute Wi thout Sponsor Approval Page [ADDRESS_14011]-approval registry:
All correspondence relating to  the registry: e.g. with another investigator, IRB, the 
sponsor, a monitor, or the FDA
Records of each patient, including case history, data forms, pa tient consent, and 
supporting documentation
A copy of the registry protocol
Signed investigator or research agreement
A copy of the IRB letter approving the research registry
A copy of the IRB approved Patient Information and Consent form
All clinical forms and d ocumentation, including:
a copy of the signed patient consent form
all supporting documentation for data entered into the EDC
records of any adverse device effects, including supporting doc umentation
records pertaining to patient de aths during the investigation
documentation and rationale for any deviations from the clinica l protocol
any other records required by [CONTACT_456]
8.2 I NVESTIGATOR REPORTS
The investigator is responsible for the accurate and timely pre paration (review and/or 
signature) and submission of the reports cited below:
Withdrawal of IRB approval and the reason for withdrawal. An in vestigator should 
report to the sponsor, within 5 working days, a withdrawal of a pproval by [CONTACT_14612]’s participation in an in vestigation.
Informed consent. If an investigator enrolls a patient without obtaining informed 
consent, the investigator will report such enrollment to the sp onsor and the 
reviewing IRB within [ADDRESS_14012]-approval registry
Annual progress reports prepared for the IRB
CELESTIAL R EGISTRY PROTOCOL
Revision: 16-NOV-2010 CONFIDENTIAL: Do Not Copy or Distribute Wi thout Sponsor Approval Page 31
Notification of any deviations from the investigational protoco l
Final summary report prepared for the IRB
Other: an investigator will, upon request by a reviewing IRB, th e FDA, or 
BIOTRONIK, provide accurate, complete, and current information about any 
aspect of the registry
The table below is a chart outlining the responsibilities, incl uding time constraints, for
submitting the above reports.
Type of Report Prepared by 
[CONTACT_14613]:Time Constraints of Notification
Patient Death During 
InvestigationBIOTRONIK, IRB BIOTRONIK as soon as possible and 
as required by [CONTACT_14614] [ADDRESS_14013] life or physical well-being of the patient, otherwise prior approval by [CONTACT_14615], IRB Within 5  working days of use
Final Summary Report BIOTRONIK, IRB Within 3 months after complet ion or 
termination of the registry
8.3 S PONSOR RECORDS
The sponsor, BIOTRONIK, will maintain the following records:
All correspondence that pertains to the investigation with inve stigator(s), IRB, 
and FDA
Investigator agreements, financia l disclosures, and current cur riculum vitae
Name [CONTACT_14624] (pro tocol) and report of prior inv estigations
Monitoring reports
Clinical progress reports
CELESTIAL R EGISTRY PROTOCOL
Revision: 16-NOV-2010 CONFIDENTIAL: Do Not Copy or Distribute Wi thout Sponsor Approval Page 32
8.4 S PONSOR REPORTS
The sponsor is responsible for pr eparing the following reports:
Type of Report Prepared by [CONTACT_14616]:Time Constraints of Notificatio n
Withdrawal of IRB 
ApprovalFDA, all reviewing IRBs,
and participating investigatorsWithin 5 working days of receipt of 
notice of withdrawal of approval
Withdrawal of FDA ApprovalReviewing IRBs and 
participating investigatorsNotification will be made within 5 
working days
Progress Report FDA, all reviewing  IRBs A periodic progress report  will be 
submitted every six months. The report will include:
All reported AEs
AE trend analysis
Patient accountability, including enrollment, and follow-up status
Recall and Disposition FDA, all re viewing IRBs Notification will be made within [ADDRESS_14014] that an investigator return, repair or 
otherwise dispose of any devices
Final Report FDA, all reviewing IRBs,
and participating 
investigatorsNotify FDA within 30 working days 
of the completion or termination of 
the investigation. A final report will 
be submitted within 6 months after 
completion or termination of the registry.
Failure to Obtain Informed ConsentFDA A copy of the investigator's report 
will be submitted within 5 working days of notification of use
CELESTIAL R EGISTRY PROTOCOL
Revision: 16-NOV-2010 CONFIDENTIAL: Do Not Copy or Distribute Wi thout Sponsor Approval Page 33
APPENDIX A: DEFINITION OF TERMS
AE(Adverse Event) - an unwanted effect detected in participants. Th e term is used 
whether or not the effect can be attributed to the leads in the  registry. For the purposes 
of this registry, BIOTRONIK classifies an AE as either related t o the Corox BP lead or 
not related to the lead.
ACC/AHA – American College of Cardiology/American Heart Association
Cardiac Perforation – Penetration of the lead tip through the myocardium (including 
microperforation), either clinica lly suspected or confirmed by [CONTACT_13190] x-ray, fluoroscopy, 
echocardiogram, intracardiac electrogram and/or visually
Clinical Failure – Inability of the Corox BP LV lead to correctly sense or pace i n the 
heart, not attributable to a mechanical malfunction of the lead  or pulse generator that 
remains unresolved despi[INVESTIGATOR_14590]/or repositioning. 
CFR – Code of Federal Regulations 
Conductor Fracture – See Lead Fracture
Confirmed Failure – A Corox BP LV lead having clinically relevant characteristics that 
are outside the performance limits established by [CONTACT_14617], as confirmed by [CONTACT_14618], except for changes in charac teristics that are due to 
induced malfunctions. Lead damage caused during or after explant  is not considered a 
failure.
Complication - an adverse event that requires additional invasive interventio n to 
resolve
Coronary Sinus Dissection – A tear that occurs in the wall of the coronary sinus
Coronary Perforation - Penetration of the lead tip through the coronary sinus, either 
clinically suspected or confirmed by [CONTACT_13190] x-ray, fluoroscopy, echocardiogram, 
intracardiac electrogram and/or visually
CHF (Congestive Heart Failure) – a condition where the heart is not able to pump 
sufficient amounts of blood  to meet the body’s need
CRT-P – Cardiac Resynchronization Therapy Pacemaker
CRT-D - Cardiac Resynchronization Therapy Defibrillator
Defibrillation Impedance – The total opposition of current that presents in the circuit 
utilized to shock an arrhythmic heart back into a normal rhythm . Defibrillation 
impedance is considered abnorm al if the measurement is 20 Ohms or 200 Ohms
Diaphragmatic/Pectoral Stimulation – Clinical observation of inadvertent 
nerve/muscle stimulation other than cardiac muscle.
eCRF – electronic Case Report Form
EDC – Electronic Data Capture system
CELESTIAL R EGISTRY PROTOCOL
Revision: 16-NOV-2010 CONFIDENTIAL: Do Not Copy or Distribute Wi thout Sponsor Approval Page 34
Elevated Threshold – Either of the following definitions constitute an Elevated 
Threshold:
1. At implant, pacing thresholds for the permanently programmed electrode that are 
greater than 3.0 Volts at 0.5 ms., or
2. At follow-up, pacing thresholds for the permanently programme d electrode that 
are greater than 3.5 Volts at 0.5 ms.
ERI– Elective Replacement Indicator
Exit Block – The failure of an intact pacing system to capture the heart bec ause the 
stimulation threshold exceeds the output of the pacemaker
Explanted (LV Lead) – Surgical removal of an LV lead during the acute implant stage,  
whereby [CONTACT_14619] (LV Lead) - Surgical removal of a chronically implanted LV lead 
Failure to Capture or Loss of Capture – Intermittent or complete failure to achieve 
cardiac stimulation at programmed output delivered outside of t he cardiac refractory 
period
High Pacing Threshold – Sudden and significant increase compared to the previous 
measured threshold value
IDE– Investigational Device Exemption
Insulation Breach/Break – Visual, electrical, or radiographic evidence of a disruption 
or break in the insulation of a lead
IRB– Investigational Review Board
Lead Dislodgment or Lead Migration – Radiographic, electrical or 
electrocardiographic evidence of e lectrode displacement from th e original implant site or 
electrode displacement that adversely affects pacing, and/or le ad performance
Lead Fracture – Visual, electrical and/or radiographic evidence of mechanical break 
within the lead conductor (connec tors, coils and/or electrodes)
Lead impedance out of range – Pacing impedance is considered abnormal if a 
measurement is 200 Ohms or 2000 Ohms
Loss of Sensing/Undersensing– Intermittent or complete failure to sense any intrinsic 
events that occur outside the programmed refractory periods at programmed sensitivity 
settings
LV– Left Ventricular
LV Lead Abandoned, CRT programmed off – The LV lead remains connected to the 
generator but LV pacing is disabled
Non-healing Pocket Dehiscence – Separation of wound edges around the pocket of 
the implanted pulse generator that have not healed
CELESTIAL R EGISTRY PROTOCOL
Revision: 16-NOV-2010 CONFIDENTIAL: Do Not Copy or Distribute Wi thout Sponsor Approval Page 35
NYHA – [LOCATION_001] Heart Association, a recognized system of classifying patient 
condition according to:
I – Ordinary physical activity does not cause undue fatigue, palp itation, 
dyspnea, or anginal pain
II – Ordinary physical activity results in fatigue, palpi[INVESTIGATOR_332], dyspnea, or anginal 
pain
III – Less than ordinary physical ac tivity causes fatigue, palpit ation, dyspnea or 
anginal pain
IV – Symptoms of cardiac insufficiency or of the anginal syndrom e may be 
present even at rest. If any physical activity is undertaken, d iscomfort is 
increased
Observation – an adverse event that does not require additional invasive inter vention 
to resolve
Oversensing – Misinterpretation of cardiac or non-cardiac events as cardiac 
depolarization, such as T waves, skeletal muscle potentials, an d extracardiac 
electromagnetic interference (EMI)
PG (Pulse Generator) – For this registry, the pulse generator must be either a 
BIOTRONIK CRT-P or CRT-D
Pneumothorax – Air or fluid in the pleural space surrounding the lung leading to  
collapse or partial collapse of the lung
Premature Battery Depletion – Reaching Elective Replacement indicator (ERI) before 
the predicted date
Mechanical Failure – Malfunction of the Corox BP LV lead through a break in the 
conductor, insulation or connector pin leading to loss of CRT t herapy
RV/RA/ICD lead – Right Ventricular/ Right Atrial/  Implantable Cardioverter Defi brillator 
Lead
Significant Increase in Pacing Threshold – One of the following definitions must be 
met:
1. An observed increase of 2-fold over the first chronic thresho ld, provided that the 
resultant threshold is greater than 5 Volts at 0.5 ms, or
2. An observed threshold higher than the maximum output of the d evice. Currently, 
this is 7.5 V at 1.5 ms in the Lumax 340 HF-T and Lumax 540 HF-T  CRT-D’s.
Chronic threshold is defined as the pacing threshold determined  at the patient’s 3 month 
follow-up visit.
Skin Erosion – Deterioration of tissue over an implanted device or the movemen t of a 
lead toward or through the skin
Suspected Generator Failure – Pulse generator issue that is potentially an electrical 
malfunction
CELESTIAL R EGISTRY PROTOCOL
Revision: 16-NOV-2010 CONFIDENTIAL: Do Not Copy or Distribute Wi thout Sponsor Approval Page 36
Suspected Lead Failure – Corox BP LV Lead issue that is potentially a mechanical or 
electrical malfunction
Tamponade – Compression of the heart caused by [CONTACT_14620] – An observed threshold increase of 2-fold over the first chronic  
threshold, provided that the resu ltant threshold is greater than  3.5 Volts at 0.5 ms. 
Chronic threshold is defined as the pacing threshold determined at the patient’s 3 month 
follow-up visit.
Thrombosis – The development of a blood clot in a vein or artery
Twiddler’s Syndrome – A condition where the pulse generator leads are dislodged by 
[CONTACT_14621] R EGISTRY PROTOCOL
Revision: 16-NOV-2010 CONFIDENTIAL: Do Not Copy or Distribute Wi thout Sponsor Approval Page 37
APPENDIX B: TIMELINE
CELESTIAL Post-Approval Registry Timeline
While BIOTRONIK has legally marketed and sold cardiac rhythm ma nagement devices 
for many years, Cardiac Resynchronization Therapy is a relative ly new field for 
BIOTRONIK. Creating a timeline that characterizes patient enroll ment where market-
share is not clearly understood is challenging, and therefore B IOTRONIK has made the 
following assumptions:
FDA protocol approval  by [CONTACT_14622] 8, 2008
Ability to recruit sufficient number of interested centers and enroll 2500 patients 
within 24 months
10% local IRB, 90% central IRB
In addition, BIOTRONIK assumes the approximate timeline:
CELESTIA LPost-Approval Registr yTimeline Estimate Date
FDA Approval of the Corox BP LV Leads (P070008) May 12, [ADDRESS_14015]-Approval Registry Status Report submitted N ovember 08, 2017